Cargando…

Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures

PURPOSE: The aim of this study was to assess the levels of selected markers in patients who underwent planned or emergency coronary angiography and to examine if they correlated with the occurrence of AKI. METHODS: The study included 52 patients who underwent planned or emergency coronary angiograph...

Descripción completa

Detalles Bibliográficos
Autores principales: Zdziechowska, Magdalena, Gluba-Brzózka, Anna, Poliwczak, Adam R., Franczyk, Beata, Kidawa, Michał, Zielinska, Marzenna, Rysz, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575457/
https://www.ncbi.nlm.nih.gov/pubmed/32557377
http://dx.doi.org/10.1007/s11255-020-02530-x
_version_ 1783597813856206848
author Zdziechowska, Magdalena
Gluba-Brzózka, Anna
Poliwczak, Adam R.
Franczyk, Beata
Kidawa, Michał
Zielinska, Marzenna
Rysz, Jacek
author_facet Zdziechowska, Magdalena
Gluba-Brzózka, Anna
Poliwczak, Adam R.
Franczyk, Beata
Kidawa, Michał
Zielinska, Marzenna
Rysz, Jacek
author_sort Zdziechowska, Magdalena
collection PubMed
description PURPOSE: The aim of this study was to assess the levels of selected markers in patients who underwent planned or emergency coronary angiography and to examine if they correlated with the occurrence of AKI. METHODS: The study included 52 patients who underwent planned or emergency coronary angiography and received contrast agent. Serum levels of markers (NGAL, L-FABP, KIM-1, IL-18) were analyzed in all patients using ELISA tests, at baseline, after 24 and 72 h from angiography. RESULTS: 9.62% of patients developed CI-AKI. No significant differences were observed between markers levels in patients who developed CI-AKI and those who did not. After 24 h, serum levels of IL-18 were higher in patients with CI-AKI, however, this difference was on the verge of significance. Increase in serum NGAL, KIM-1 and IL-18 was observed after 24 h. Serum levels of biomarkers were insignificantly higher in group with CI-AKI. Significant changes in levels in time (baseline vs. 24 h vs. 72 h) were observed only for NGAL [157.9 (92.4–221.0) vs. 201.8 (156.5–299.9) vs. 118.5 (73.4–198.7); p < 0.0001]. No significant correlations were observed between the decrease in eGFR or the increase in creatinine and biomarkers level. CONCLUSION: Obtained results do not allow for the indication of efficient AKI biomarkers. Their further validation in large studies of CI-AKI patients is required.
format Online
Article
Text
id pubmed-7575457
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-75754572020-10-21 Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures Zdziechowska, Magdalena Gluba-Brzózka, Anna Poliwczak, Adam R. Franczyk, Beata Kidawa, Michał Zielinska, Marzenna Rysz, Jacek Int Urol Nephrol Nephrology - Original Paper PURPOSE: The aim of this study was to assess the levels of selected markers in patients who underwent planned or emergency coronary angiography and to examine if they correlated with the occurrence of AKI. METHODS: The study included 52 patients who underwent planned or emergency coronary angiography and received contrast agent. Serum levels of markers (NGAL, L-FABP, KIM-1, IL-18) were analyzed in all patients using ELISA tests, at baseline, after 24 and 72 h from angiography. RESULTS: 9.62% of patients developed CI-AKI. No significant differences were observed between markers levels in patients who developed CI-AKI and those who did not. After 24 h, serum levels of IL-18 were higher in patients with CI-AKI, however, this difference was on the verge of significance. Increase in serum NGAL, KIM-1 and IL-18 was observed after 24 h. Serum levels of biomarkers were insignificantly higher in group with CI-AKI. Significant changes in levels in time (baseline vs. 24 h vs. 72 h) were observed only for NGAL [157.9 (92.4–221.0) vs. 201.8 (156.5–299.9) vs. 118.5 (73.4–198.7); p < 0.0001]. No significant correlations were observed between the decrease in eGFR or the increase in creatinine and biomarkers level. CONCLUSION: Obtained results do not allow for the indication of efficient AKI biomarkers. Their further validation in large studies of CI-AKI patients is required. Springer Netherlands 2020-06-17 2020 /pmc/articles/PMC7575457/ /pubmed/32557377 http://dx.doi.org/10.1007/s11255-020-02530-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Nephrology - Original Paper
Zdziechowska, Magdalena
Gluba-Brzózka, Anna
Poliwczak, Adam R.
Franczyk, Beata
Kidawa, Michał
Zielinska, Marzenna
Rysz, Jacek
Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures
title Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures
title_full Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures
title_fullStr Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures
title_full_unstemmed Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures
title_short Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures
title_sort serum ngal, kim-1, il-18, l-fabp: new biomarkers in the diagnostics of acute kidney injury (aki) following invasive cardiology procedures
topic Nephrology - Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575457/
https://www.ncbi.nlm.nih.gov/pubmed/32557377
http://dx.doi.org/10.1007/s11255-020-02530-x
work_keys_str_mv AT zdziechowskamagdalena serumngalkim1il18lfabpnewbiomarkersinthediagnosticsofacutekidneyinjuryakifollowinginvasivecardiologyprocedures
AT glubabrzozkaanna serumngalkim1il18lfabpnewbiomarkersinthediagnosticsofacutekidneyinjuryakifollowinginvasivecardiologyprocedures
AT poliwczakadamr serumngalkim1il18lfabpnewbiomarkersinthediagnosticsofacutekidneyinjuryakifollowinginvasivecardiologyprocedures
AT franczykbeata serumngalkim1il18lfabpnewbiomarkersinthediagnosticsofacutekidneyinjuryakifollowinginvasivecardiologyprocedures
AT kidawamichał serumngalkim1il18lfabpnewbiomarkersinthediagnosticsofacutekidneyinjuryakifollowinginvasivecardiologyprocedures
AT zielinskamarzenna serumngalkim1il18lfabpnewbiomarkersinthediagnosticsofacutekidneyinjuryakifollowinginvasivecardiologyprocedures
AT ryszjacek serumngalkim1il18lfabpnewbiomarkersinthediagnosticsofacutekidneyinjuryakifollowinginvasivecardiologyprocedures